JPMorgan Chase & Co. Buys 424,937 Shares of Qiagen (NYSE:QGEN)

JPMorgan Chase & Co. boosted its position in shares of Qiagen (NYSE:QGEN) by 36.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,604,034 shares of the company’s stock after purchasing an additional 424,937 shares during the quarter. JPMorgan Chase & Co. owned 0.70% of Qiagen worth $73,096,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the period. Toronto Dominion Bank acquired a new position in shares of Qiagen in the 2nd quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV raised its holdings in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after buying an additional 243 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen in the third quarter valued at approximately $53,000. Finally, Headlands Technologies LLC raised its holdings in shares of Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after acquiring an additional 2,189 shares during the period. Institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several recent research reports. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $54.00 price objective (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Qiagen presently has an average rating of “Moderate Buy” and an average target price of $51.88.

Qiagen Stock Performance

Shares of NYSE:QGEN opened at $44.97 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The company’s 50 day moving average price is $43.75 and its two-hundred day moving average price is $43.82. The firm has a market cap of $10.26 billion, a PE ratio of 115.31, a PEG ratio of 3.52 and a beta of 0.35.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.